Secondary Logo

Institutional members access full text with Ovid®

Combination of SF1126 and gefitinib induces apoptosis of triple-negative breast cancer cells through the PI3K/AKT–mTOR pathway

Deng, Miao; Wang, Jianguang; Chen, Yanbin; Zhang, Like; Liu, Dechun

doi: 10.1097/CAD.0000000000000202
PRECLINICAL REPORTS
Buy
SDC

To investigate the apoptotic mechanism of triple-negative breast cancer (TNBC) cells induced by gefitinib and PI3K inhibitor SF1126. MDA-MB-231, MDA-MB-436, and MCF-7 cells were incubated with 0.1 μmol/l gefitinib, 1 μmol/l gefitinib, 10 μmol/l gefitinib, 1 μmol/l SF1126, 0.1 μmol/l gefitinib+1 μmol/l SF1126, 1 μmol/l gefitinib+1 μmol/l SF1126, and 10 μmol/l gefitinib+1 μmol/l SF1126. Then, cell viability and survival were determined using an 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyltetrazolium bromide (MTT) assay and Hoechst staining. The apoptosis-related factors and phosphoinositide-3-kinase/protein kinase B, the mammalian target of rapamycin (PI3K/AKT–mTOR) signaling pathway-related factors were detected by western blot. For TNBC cells, cell viability or survival was not significantly inhibited by gefitinib or SF1126 alone; however, marked cell apoptosis was noted in the gefitinib and SF1126 combination groups, and this effect was dose dependent. Also, the expressions of apoptosis markers, such as cleaved caspase-3, Bcl-2/Bax, were altered by the gefitinib and SF1126 combination. Moreover, phosphorylated AKT (p-AKT) and 70 kDa ribosomal protein S6-kinase (p-p70S6K) were also inhibited by the gefitinib and SF1126 combination, which may be responsible for the apoptosis. Gefitinib combined with SF1126 could induce cell apoptosis in TNBC cells and this effect was mediated through the EGFR-PI3K-AKT-mTOR-p70S6K pathway. Our studies have set the stage for future clinical trials of TNBC therapy by the combination of gefitinib and SF1126.

Supplemental Digital Content is available in the text.

Department of Breast Surgery, The First Affiliated Hospital of the Henan University of Science and Technology, Luoyang, Henan, People’s Republic of China

Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's website (www.anti-cancerdrugs.com).

Correspondence to Dechun Liu, MD, Department of Breast Surgery, The First Affiliated Hospital of the Henan University of Science and Technology, Luoyang, Henan 471003, People’s Republic of China Tel: +86 379 648 307 80; fax: +86 379 6483 0780; e-mail: liudechun2013@126.com

Received July 15, 2014

Accepted December 2, 2014

Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.